<DOC>
	<DOCNO>NCT01341808</DOCNO>
	<brief_summary>The purpose study measure immune response 18-40 year old IBD patient receive hepatitis A vaccine .</brief_summary>
	<brief_title>Immunogenicity Hepatitis A Vaccine Inflammatory Bowel Disease ( IBD ) Patients</brief_title>
	<detailed_description>The spread hepatitis A prompt need vaccination virus . It uncertain IBD patient achieve truly protective response vaccination . The efficacy safety hepatitis A vaccination evaluate population patient . We would like estimate efficacy safety vaccination hepatitis A patient IBD .</detailed_description>
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Ulcer</mesh_term>
	<mesh_term>Colitis , Ulcerative</mesh_term>
	<mesh_term>Crohn Disease</mesh_term>
	<mesh_term>Colitis</mesh_term>
	<mesh_term>Intestinal Diseases</mesh_term>
	<mesh_term>Inflammatory Bowel Diseases</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>1 . Patients suffer inflammatory bowel disease : Crohn 's disease/Ulcerative colitis 2 . Age 1840 3 . Willing provide inform consent 1 . Have history vaccination hepatitis A 2 . Have autoimmune disease 3 . Have malignancy 4 . Have acute infectious disease 5 . Unwilling provide consent</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>40 Years</maximum_age>
	<verification_date>March 2013</verification_date>
	<keyword>Crohn 's disease</keyword>
	<keyword>Ulcerative colitis</keyword>
	<keyword>Hepatitis A</keyword>
	<keyword>vaccine</keyword>
</DOC>